Skip to content
Review Open access

Gut Microbiome‐Targeted Preventive Strategies for Polyendocrine Metabolic Ovarian Syndrome: Insights From the Prenatal and Early‐Life Environment

Jan 2026 · Reproductive Medicine and Biology · Vol 25 · 0 citations · 128 references
Medicine

TL;DR

It is suggested that prenatal and early postnatal environments shape gut microbiota establishment and maturation, which may interact with multiple developmental pathways and potentially modify susceptibility to PMOS later in life.

Abstract

ABSTRACT Background Polyendocrine metabolic ovarian syndrome (PMOS), the proposed new name for polycystic ovary syndrome (PCOS), is a complex endocrine and metabolic disorder influenced by genetic and environmental factors. Despite its high prevalence and familial aggregation, no effective preventive strategy is available. Prenatal androgen exposure is considered a key factor in PMOS pathogenesis, with studies indicating a significant role for the gut microbiome. Methods This review summarizes evidence from human and animal studies exploring the association between PMOS and the gut microbiome, spotlighting the impact of the intrauterine environment, including prenatal androgen exposure and maternal gut microbiome, in PMOS development. Main Findings Gut microbiota dysbiosis is associated with features of PMOS pathophysiology, including hyperandrogenism, insulin resistance, neuroendocrine dysfunction, and ovarian dysfunction. Emerging evidence suggests that prenatal and early postnatal environments shape gut microbiota establishment and maturation, which may interact with multiple developmental pathways and potentially modify susceptibility to PMOS later in life. Conclusion The gut microbiome may be involved in the developmental origins and pathophysiology of PMOS, although its precise role remains unclear. Understanding early‐life host‐microbiome interaction may provide a foundation for future preventive and personalized management strategies for PMOS, but further mechanistic studies and clinical validation are required.

Read PDF

Similar papers

Review Aug 2026

Polyendocrine Metabolic Ovarian Syndrome (PMOS; Formerly Polycystic Ovary Syndrome/PCOS) and Susceptibility to Microbial Infections: Mechanisms, Clinical Management, and Reproductive Consequences — A Comprehensive Review

Evidence suggests that women with PMOS may be more vulnerable to selected infection-related conditions, especially vaginal dysbiosis, bacterial vaginosis, and vulvovaginal candidiasis, so clinical care should focus on established PMOS management, metabolic optimization, risk-based infection evaluation, and treatment of...

A. Samareh, Mohammad Samare-Najaf, M. Ghafari et al. · 0 citations
Review Open access Sep 2026

Ketogenic diet combined with probiotics for polyendocrine metabolic ovarian syndrome: research progress from the perspective of the gut microbiota–host metabolic axis

The ketogenic diet (KD) and probiotics may improve PMOS by restricting carbohydrate intake, promoting ketone production, reducing body weight, enhancing insulin sensitivity, and alleviating inflammation, but these changes may also decrease beneficial bacteria, including Bifidobacterium, potentially disrupting intestina...

Yi Yang, Fu-Ren Dai, Xiao-Ming He et al. · 0 citations
Open access Sep 2026

Gut microbiota variation in admixed Hispanic populations with polyendocrine metabolic ovarian syndrome

It is suggested that PMOS is not characterized by major gut microbiome shifts but may involve subtle depletion of health-associated commensals and increased microbial heterogeneity.

Loida A. González-Rodríguez, Keishla M. Jimenez-Ortega, D. Vargas-Robles et al. · 0 citations
Review Open access Sep 2026

Microbial Dysbiosis, Infection, and Immunometabolic Signaling in Polyendocrine Metabolic Ovarian Syndrome (Formerly PCOS)

Polyendocrine metabolic ovarian syndrome (PMOS), recently proposed as a new name for polycystic ovary syndrome (PCOS), is a heterogeneous endocrine–metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and variable ovarian morphology. Low-grade inflammation is common, but its initiating and susta...

Allyson W. Nevins, N. Stansbury, R. Robinson et al. · 0 citations
Open access Sep 2026

Gypenosides ameliorate polycystic ovary syndrome via gut microbiota modulation: An integrated gut microbiome and ovarian transcriptome study

Summary Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with complex metabolic and reproductive manifestations. Gut microbiota dysbiosis has emerged as a key factor in PCOS, yet the causal role of microbiota-targeted interventions remains to be fully defined. In a letrozole-induced rat model, we show...

Shao-Rong Li, Jiang-Fan Wan, Zhi-Jie Liang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.